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Abstract 
Background: Gliptins should have beneficial effects beyond glycemic control, potentially on the pathophysiology 
of cardiovascular (CV) diseases, with some basic studies demonstrating this possibility. However, we are yet to answer 
whether there are any direct CV effects in the clinical setting. We aimed to examine the beneficial effects of sitagliptin 
in Japanese patients with diabetes and high CV risk for 12 months.
Methods: This was a prospective, multicenter, observational study of 205 patients with type 2 diabetes. All partici-
pants had more than one major CV risk factor and were treated with sitagliptin for 12 months. At 3 or 12 months, we 
examined the effects of treatment on glycemic control, CV function (by electrocardiography, echocardiography, and 
reactive hyperemia-peripheral arterial tonometry), and CV biomarkers.
Results: Patients were predominantly elderly (68.8 ± 9.9 years) and male (71.5 %) and typically had more than three 
CV risk factors (79.2 %). Treatment with sitagliptin significantly reduced the hemoglobin A1c (HbA1c) level from 
7.09 % ± 0.81 % at baseline to 6.67 % ± 0.69 % at 3 months and 6.68 % ± 0.73 % at 12 months (both P < 0.001). The 
reduction in HbA1c was also in tandem with the decrease in the level of high-sensitive C-reactive protein throughout 
the study. Independent of the change in HbA1c, sitagliptin reduced systolic (−7.0 ± 18.9 mmHg) and diastolic blood 
pressure (−5.1 ± 11.7 mmHg) at 12 months, and this was associated with a decrease in urinary albumin. In contrast, 
there were no beneficial effects on cardiac and endothelial function or on the levels of serum B-type natriuretic pep-
tide, high-sensitive troponin T, and urinary 8-hydroxy-2′-deoxyguanosine.
Conclusions: In Japanese patients with diabetes and multiple CV risk factors, sitagliptin showed a decrease in blood 
pressure associated with an improvement in albuminuria in addition to glycemic control.
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Keywords: Blood pressure, Cardiovascular risk, Type 2 diabetes, Sitagliptin, Urine albumin
© 2016 Nakamura et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Type 2 diabetes is strongly associated with coronary ath-
erosclerosis and vascular complications, both of which 
are responsible for worse morbidity and mortality [1]. 
Although the pathogenesis of atherosclerosis and asso-
ciated complications remains unclear [2], inflammatory 
processes may be a critical step, constituting a biological 
link between diabetes and vascular disease [3]. Optimal 
management of type 2 diabetes includes pharmacological 
interventions and life-style modification, including diet, 
exercise, and weight loss. To reduce the risk of cardiovas-
cular (CV) events, not only is pharmacological therapy 
necessary for lowering blood sugar levels but antihyper-
tensive, antihyperlipidemic, and antiplatelet therapies are 
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also needed [4]. In particular, integrated behavior modifi-
cation and targeted polypharmacy are especially benefi-
cial for patients with diabetes who are at high risk of CV 
disease (CVD) [5].
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor 
(gliptin), has been shown to increase plasma incretin hor-
mone levels, including glucagon-like peptide-1 (GLP-1) 
and glucose-dependent insulinotropic polypeptide (GIP). 
Increases in these peptides appear to be responsible for 
the principle mechanism of action of sitagliptin; as the 
levels of GLP-1 increase, glucose concentrations decrease 
[6]. Sitagliptin is known to be effective and safe as both 
monotherapy and combination therapy in patients with 
diabetes. Recently, the Trial Evaluating Cardiovascular 
Outcomes with Sitagliptin (TECOS) assessed composite 
CV endpoint and hospitalization rates for heart failure 
in patients with type 2 diabetes and established CVD, 
and demonstrated that sitagliptin was safe [7]. However, 
we still do not know the various long-term influences of 
incretin-based therapies, such as sitagliptin, on CV risk 
factors and disease, including the effects on morbidity 
and mortality.
DPP-4 is a widely expressed glycoprotein that exists 
either as a transmembrane protein or in a soluble form in 
plasma, and has many targets other than GLP-1 and GIP. 
In addition, the GLP-1 receptor is variously expressed, 
being located not only in pancreatic cells but also in the 
lungs, kidneys, intestines, peripheral and central nerv-
ous systems, and the CV system. Based on this, it has 
been suggested that gliptins should have beneficial effects 
beyond glycemic control, potentially on the pathophysi-
ology of CVD, with some basic studies demonstrat-
ing this possibility [8]. However, these effects remain 
unclear in the clinical setting [9], and the factors predic-
tive of a blood glucose-lowering effect remain unknown 
in patients with diabetes who are at high risk of CVD. 
Equally, we are yet to answer whether there are any direct 
CV effects in the medium term.
We performed this prospective study to determine 
whether sitagliptin therapy for 12 months had any benefi-
cial effects on glycemic control and CV function in Japa-
nese patients with diabetes at high risk of CVD.
Methods
Study design
This was a prospective, multicenter, observational study. 
Eligible patients with diabetes at high risk of CVD were 
treated with sitagliptin for 12 months from August 2011 
to September 2012, at nine hospitals and clinics in Japan. 
The patients received sitagliptin at dosages of 25, 50, or 
100 mg/day at the discretion of the attending physician, 
and biochemical markers, urinalysis, electrocardiogra-
phy (ECG), and echocardiography (UCG) were assessed 
before, and at 3 and 12 months after treatment. In a sub-
study at the Department of Internal Medicine, Kinki 
University Faculty of Medicine and the Tazuke Kofukai 
Medical Research Institute, Kitano Hospital, we also per-
formed reactive hyperemia-peripheral arterial tonometry 
(RH-PAT) before and at 3  months after starting sitag-
liptin and measured CV biomarkers before and at 3 and 
12 months after treatment.
The study protocol was approved by the Ethics Com-
mittee of Kinki University Faculty of Medicine and Osaka 
Foundation for the Prevention of Cancer and Cardiovas-
cular Disease. Written informed consent was obtained 
from all patients. The trial was registered at http://www.
umin.ac.jp under UMIN000005663.
Selection criteria
The inclusion criteria were as follows: (1) age ≥20 years; 
(2) type 2 diabetes with a hemoglobin A1c (HbA1c) 
≥6.2  %, a fasting glucose ≥110  mg/dL, or a postpran-
dial glucose ≥140  mg/dL despite appropriate diet and 
exercise, oral antihyperglycemic agents, or insulin ther-
apy; and (3) at least one CV risk from among hyperten-
sion, dyslipidemia, previous CV event, advanced age 
(≥65  years), current smoking, obesity (body mass index 
≥25), and hyperuricemia. Patients were excluded if they 
met the following criteria: (1) history of diabetic coma and 
ketoacidosis within 6  months before the study, (2) seri-
ous trauma or infectious disease, (3) currently nursing or 
pregnant women, (4) dialysis or severe renal insufficiency 
(creatinine clearance <30 mL/min), and (5) known hyper-
sensitivity to any component of the study medications.
Study endpoints
The primary endpoint was the change in HbA1c after 3 
and 12 months of sitagliptin therapy. The major second-
ary endpoints were changes in body weight, blood pres-
sure (BP), biochemical measures, urinary measures, ECG 
parameters, and UCG parameters.
Ambulatory BP measurement
BP was measured during office visits at baseline and after 
3 and 12 months of treatment. Cuffs were used with the 
bladder encircling at least 80 % of the mid-arm circum-
ference and placed directly on the skin. All BP measure-
ments were taken after 5 min of rest with patients sitting 
and with the arm resting on a table at the level of the 
heart.
Measurement of biochemical and urine parameters
The following parameters were measured at base-
line and after 3 and 12  months of treatment: stand-
ard urinalysis, urinary albumin, complete blood count, 
serum electrolytes, liver function, renal function, lipid 
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profile, immunoreactive insulin, and HbA1c. In the 
sub-study, we also measured the following before and 
at 3 and 12  months after treatment: urinary 8-hydroxy-
2′-deoxyguanosine (8-OHdG) as a marker of oxidative 
stress, high-sensitive C-reactive protein (hs-CRP) as 
an inflammatory marker, and both high-sensitive tro-
ponin T (hs-TnT) and B-type natriuretic peptide (BNP) 
as cardiac markers. The estimated glomerular filtra-
tion rate (eGFR) was calculated using the equation spe-
cific to the Japanese population: eGFR =  194 ×  (serum 
creatinine)−1.094  ×  (age)−0.287 (×  0.739 if female) [10]. 
Albuminuria was determined by the urinary albumin-
to-creatinine ratio (UACR). Microalbuminuria was 
defined as a UACR of 30–300 mg/g creatinine, and overt 
albuminuria as a UACR of 300–3000  mg/g creatinine. 
The homeostasis model assessment-insulin resistance 
(HOMA-IR) value was calculated using the following for-
mula: HOMA-IR  =  [fasting insulin (μIU/ml)  ×  fasting 
glucose (mg/dl)]/405.
ECG and UCG examination
ECG and UCG were performed at baseline and after 
12  months of treatment. The ECG parameters were 
examined by automatic analysis [ECG-1450 (Nihon Koh-
den, Tokyo, Japan)]. Heart rate (HR), rhythm, PR inter-
val, QRS interval, QT/corrected QT (QTc) interval, and 
the SV1  +  RV5 value were obtained [11]. In the UCG 
analysis, the chamber dimensions, left ventricular (LV) 
ejection fraction (EF), and LV mass index were assessed 
from M-mode images using the American Society of 
Echocardiography-recommended formula [12]. For 
patients in sinus rhythm, the pulsed Doppler transmi-
tral flow velocity was recorded to measure the ratio of 
peak mitral E-wave velocity to peak mitral A-wave veloc-
ity (E/A ratio) and the deceleration time of the mitral 
E-wave velocity (Dct). The peak of myocardial early dias-
tolic velocity (e′) in the septal annulus was also measured 
by tissue Doppler imaging, and the ratio of peak mitral 
E-wave velocity to e′ velocity (E/e′ ratio) was calculated 
for the assessment of LV relaxation.
Assessment of endothelial function
In the sub-study, we assessed peripheral endothelial 
function by RH-PAT using an EndoPAT2000 (Itamar 
Medical, Caesarea, Israel), as described previously [13]. 
RH-PAT was performed at baseline and after 3  months 
of treatment to calculate the reactive hyperemia index 
(RHI), which reflects the extent of reactive hyperemia, 
and thereby, endothelial function. It was calculated as 
the ratio of the average amplitude of the PAT signal over 
1 min starting at 1.5 min after cuff deflation (control arm, 
A; occluded arm, C) divided by the average amplitude 
of the PAT signal of a 2.5-min time period before cuff 
inflation (baseline) (control arm, B; occluded arm, D), as 
follows: RHI = (C/D)/(A/B).
Statistical analysis
Categorical variables were compared using the χ2 test for 
proportions and the unpaired t test or analysis of variance 
(ANOVA) for continuous variables, as appropriate. The 
linearity of the relationship between two variables was 
assessed by linear regression analysis, and Pearson’s cor-
relation coefficient was calculated. Differences between 
the reduction or increase in each marker and the change 
in HbA1c were compared using Student’s t tests. Fur-
ther multiple logistic regression analysis was performed 
to define independent variables that might predict the 
change in HbA1c. Overall differences between before and 
after sitagliptin administration were determined using 
repeated measures ANOVA. All P values <0.05 were con-
sidered statistically significant. Results are expressed as 
the mean  ±  standard deviation (SD). All analyses were 
performed using JMP version 10.0.
Results
Baseline clinical characteristics
Of the 211 patients enrolled, 6 patients were excluded 
from the analysis because they discontinued sitagliptin 
after 3 months, citing dizziness (2 patients), mild hypo-
glycemia (1 patient), headache (1 patient), or general 
malaise (1 patient). However, no severe adverse events, 
including severe hypoglycemia, were reported. One 
patient withdrew consent. The baseline characteris-
tics of the 205 participants are shown in Table  1. Most 
were male (71.5  %) and aged over 65  years (73.4  %), 
with mean systolic and diastolic BPs of 133.6  ±  19.2 
and 74.8 ± 11.6 mmHg, respectively. Three or more CV 
risk factors were present in 79.2  %, with hypertension 
being most common. However, 42.0  % had some medi-
cal history of CVD, including coronary heart disease. 
Over the study period, the mean sitagliptin dosage was 
52.0 ±  12.7  mg/day. About half of the patients (52.6  %) 
received sitagliptin monotherapy and the remainder 
received combination therapy, with the most common 
co-administered drugs being sulfonylureas (21.3  %) fol-
lowed by α-glucosidase inhibitors (17.9  %) and thiazoli-
dinediones (14.5 %).
Blood glucose and urinary changes (Table 2)
At baseline, HbA1c and fasting blood glucose were 
7.09  ±  0.81  % and 139.8  ±  33.0  mg/dL, respectively, 
and both parameters significantly reduced by 3 and 
12  months (both P  <  0.001). However, there were no 
changes in insulin, HOMA-IR, low-density lipopro-
tein cholesterol, triglyceride, or the uric acid level. Only 
high-density lipoprotein (HDL) cholesterol level reduced 
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significantly. In addition, the eGFR decreased signifi-
cantly during the study period, but changes in the UACR 
were not significant.
The changes in HbA1c (ΔHbA1c) at 3 and 12  months 
were significantly associated with the baseline HbA1c 
level (Fig.  1). When the predictive factors for ΔHbA1c 
were examined by multiple regression analysis (see 
Additional file  1: Table S1), only baseline HbA1c 
remained a significant factor for ΔHbA1c at 3  months 
(β  =  −0.608, P  <  0.001). However, at 12  months, sig-
nificant determinants of ΔHbA1c were age (β = −0.207, 
P  =  0.005), change in body weight (β  =  0.148, 
P  =  0.042), and baseline HbA1c level (β  =  −0.435, 
P < 0.001).
Pro‑inflammatory biomarkers, CV biomarkers, and CV 
function
We studied pro-inflammatory biomarkers, CV bio-
markers, and CV function in a subpopulation of 127 
patients. The hs-CRP, BNP, and urinary 8-OHdG 
levels remained unchanged after 3 and 12  months 
of sitagliptin therapy (see Additional file  2: Table 
S2), but the hs-TnT level significantly increased by 
12  months. When the changes in BNP, hs-TnT, and 
urinary 8-OHdG were divided into groups with either 
a reduction or an increase, we found no association 
with ΔHbA1c (all P = n.s.). In contrast, the changes in 
hs-CRP were significantly associated with changes in 
HbA1c at both 3 and 12 months (P = 0.030 and 0.004, 
respectively), suggesting that the effect of sitagliptin on 
HbA1c levels is blunted in patients with increased hs-
CRP levels (Fig. 1).
Among the ECG parameters, HR changed during the 
12 months of sitagliptin therapy from 61.2 ± 10.5 beats 
per minute (bpm) at baseline to 65.0  ±  11.9  bpm at 
12  months (P  <  0.01). However, although the QT inter-
val shortened significantly (427.9 ±  34.0  ms at baseline 
to 417.9  ±  34.5  ms at 12  months, P  <  0.001), the QTc 
interval did not change (428.1 ±  22.6  ms at baseline to 
425.2 ± 21.9 ms at 12 months, P = 0.093). Other param-
eters did not change, including the rhythm, PR interval, 
QRS interval, and SV1 + RV5 value.
Table 1 Baseline clinical characteristics
Values are the mean ± SD or %
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ASO arteriosclerosis obliterans, BMI body mass index
N = 205
Age (years) 68.8 ± 9.9 (37–88)
Male (%) 71.5
BMI (kg/m2) 25.7 ± 4.1
Blood pressure (systolic/diastolic) (mmHg) 133.6 ± 19.2/74.8 ± 11.6
Cardiovascular risk factors ≥3 (%) 79.2
 Hypertension 87.0
 Dyslipidemia 65.2
 Cardiovascular disease 42.0
  Coronary artery disease 39.6
  ASO 2.4
  Cerebral infarction 2.9
 Senior (≥65 years) 73.4
 Current smoking 16.6
 Obesity (BMI ≥25) 52.9
 Hyperuricemia (≥7.0 mg/dL) 19.9
Combination of oral hypoglycemic drugs (%) Pre- Post-
 None 52.6 56.3
 Sulfonylurea 21.3 19.4
 α-Glucosidase inhibitor 17.9 16.5
 Thiazolidinedione 14.5 12.6
 Biguanide 10.6 10.6
 Glinide 6.3 2.4
ACEI/ARB 63.6
Calcium channel blocker 41.5
Statin 58.3
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In the UCG examination, the LV mass index signifi-
cantly decreased during the 12  months of treatment, 
from 109.9  ±  33.5  g/m2 at baseline to 105.1  ±  31.9  g/
m2 at 12  months (P  =  0.027). However, the other 
parameters, including LV dimension, EF, E/A, Dct, e′, and 
E/e′, showed no changes between baseline and 12 months 
(Table  3). In the RH-PAT analysis, the RHI did not 
change by 3 months of sitagliptin treatment (1.92 ± 0.48 
Table 2 Serial changes in clinical and laboratory parameters
Values are the mean ± SD or %
Cr Creatinine, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, HOMA-R 
homeostasis model assessment-insulin resistance, IRI immunoreactive insulin, LDL-C low-density lipoprotein cholesterol, UACR albumin-to-creatinine ratio
Baseline 3 months 12 months P value
Body weight (kg) 67.3 ± 14.0 67.5 ± 14.1 67.9 ± 14.1 0.042
HbA1c (%) 7.09 ± 0.81 6.68 ± 0.69 6.69 ± 0.72 <0.001
FPG (mg/dL) 139.8 ± 33.0 130.2 ± 27.2 131.7 ± 29.0 <0.001
IRI (IU) 11.3 ± 10.1 12.4 ± 14.3 11.8 ± 11.1 0.720
HOMA-R 3.9 ± 3.8 3.9 ± 3.8 3.9 ± 3.8 0.914
 Insulin resistance (HOMA-R ≥2.5) (%) 54.7 49.4 51.4
LDL-C (mg/dL) 100.0 ± 24.2 101.4 ± 26.8 99.5 ± 28.6 0.509
HDL-C (mg/dL) 52.4 ± 14.1 51.8 ± 13.4 50.0 ± 12.0 0.036
Triglyceride (mg/dL) 136.1 ± 77.6 131.5 ± 71.8 133.6 ± 68.4 0.308
Uric acid (mg/dL) 5.9 ± 1.2 6.0 ± 1.4 5.8 ± 1.3 0.054
Cr (mg/dL) 0.86 ± 0.25 0.88 ± 0.27 0.88 ± 0.30 <0.001
eGFR (mL/min/1.73 m2) 67.7 ± 18.3 66.3 ± 18.3 66.6 ± 18.6 0.009
 eGFR <60 (%) 35.9 40.3 35.3
UACR (mg/g Cr) 79.8 ± 211.4 119.3 ± 483.2 100.5 ± 239.9 0.693
 Micro- or overt-albuminuria (%) 40.2 46.3 39.5
Fig. 1 HbA1c change (ΔHbA1c) by baseline HbA1c categories and the relationship with hsCRP change (ΔhsCRP). HbA1c hemoglobin A1c, hs-CRP 
high-sensitive c-reactive protein, M month. The values are mean ± SD
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at baseline to 1.87 ± 0.80 at 3 months, P = 0.648), and the 
proportion of patients with an RHI ≤ 1.67 did not change 
significantly from baseline to 12 months (51.6–42.4 %).
Changes in BP and renal function
The results are summarized in Fig.  2. During treatment, 
systolic BP (SBP) and diastolic BP (DBP) were signifi-
cantly reduced from baseline (SBP, 133.6 ± 19.2 mmHg; 
DBP, 74.8  ±  11.6  mmHg) to 12  months (SBP, 
127.5 ± 16.4 mmHg; DBP, 70.1 ± 12.4 mmHg). The pro-
portion of patients with a BP ≥140/90 mmHg significantly 
decreased from baseline to 12 months (33.7–25.3 %). Of 
the 94 patients who used an antihypertensive agent at 
baseline and completed the 12-month assessment period, 
15 (16.0  %) changed the drug or the dosage during the 
period. When these patients were excluded, significant 
changes were still observed in SBP and DBP at 12 months 
(−11.7  ±  18.6 and −7.3  ±  11.6  mmHg for ΔSBP and 
ΔDBP, respectively). However, ΔHbA1c by 12 months was 
associated with neither ΔSBP (r = 0.046, P = 0.318) nor 
ΔDBP (r = 0.099, P = 0.199). In addition, HR increased 
from 66.9 ± 13.0 bpm at baseline to 71.3 ± 12.9 bpm at 
12 months. However, ΔHR was not associated with ΔSBP 
(r = 0.046, P = 0.563) or ΔDBP (r = 0.036, P = 0.644) at 
12 months (see Additional file 3: Figure S1).
Albuminuria at baseline was positively associated with 
SBP at baseline. Moreover, the changes in albuminuria 
(ΔAU) and in systolic BP (ΔSBP) over 12  months were 
significantly associated; patients with a reduction in albu-
minuria (n = 63) showed a greater reduction of SBP over 
the same period than those with an increase in albuminu-
ria (n = 57) (ΔSBP; −14.3 ± 19.3 vs. −6.2 ± 14.6 mmHg, 
respectively). The tertile of ΔSBP (n = 40 each) was nega-
tively correlated with a decrease in albuminuria (P = 0.045). 
In contrast, although ΔSBP or ΔDBP was significantly asso-
ciated with ΔeGFR (r =  0.193, P =  0.012 and r =  0.256, 
P  <  0.001, respectively) (see Additional file  3: Figure S1), 
ΔAU and ΔeGFR were not associated after 12  months 
of treatment (r = 0.079, P = 0.375). Finally, ΔAU was not 
associated with ΔHbA1c (r = 0.046, P = 0.604).
Discussion
Gliptins can exert favorable cardiovascular effects in 
experimental models. These changes, as an almost gen-
eral rule, include improved endothelial function, reduc-
tion of inflammatory markers, oxidative stress, ischemia/
reperfusion injury and atherogenesis. In addition, 
increased adiponectin levels and modest decreases in 
lipidemia and blood pressure were reported [8]. Unfortu-
nately, the favorable DPP4 inhibition features reported in 
experimental studies are not necessarily reflected in clini-
cal studies [7] and a definite relationship between gliptins 
treatment and improved CV outcomes remains uncertain 
and requires further clarification [9, 14]. This could be 
due to the fact that in addition to the activation of incre-
tin hormones, gliptins are multi-target compounds and 
may therefore affect various additional substrates, lead-
ing to undesirable effects [15].
Effect of sitagliptin on CV function and biomarkers
Interestingly, the reduction in hs-CRP levels was inde-
pendently associated with the reduction in HbA1c levels. 
A recent cross-over study showed that 6 weeks of treat-
ment with sitagliptin significantly reduced the plasma 
levels of CRP and that there was a significant inverse 
correlation between changes in GLP-1 and CRP levels 
following sitagliptin therapy (r  =  0.41, P  =  0.01) [16]. 
In the present study, sitagliptin did not significantly 
decrease hs-CRP levels (P  =  0.0994), and the baseline 
hs-CRP level was not associated with ΔHbA1c (data not 
shown); therefore, the causal relationship between these 
factors remains unknown. However, these data suggest 
that there is a relationship between improvements in glu-
cose–insulin homeostasis and low-grade inflammation 
that is somehow mediated by sitagliptin therapy in dia-
betic subjects with high CV risk.
Table 3 Changes in electrocardiography and echocardiog-
raphy parameters
Values are the mean ± SD or %
Dct deceleration time, Dd dimension of diastole, Ds dimension of systole, EF 
ejection fraction, HR heart rate, IVST interventricular septal thickness, LV left 
ventricular PWT posterior wall thickness
Baseline 12 months P value
Electrocardiography parameters
 HR (bpm) 61.2 ± 10.5 65.0 ± 11.9 <0.0001
 Sinus rhythm (%) 90.1 89.0
 PR interval (ms) 179.5 ± 32.2 180.5 ± 31.4 0.5784
 QRS interval (ms) 98.0 ± 19.1 97.9 ± 18.2 0.7720
 SV1 + RV5 voltage (mm) 2.7 ± 0.8 2.6 ± 0.7 0.1288
 QT interval (ms) 427.9 ± 34.0 417.9 ± 34.5 0.0004
 QTc interval (ms) 428.1 ± 22.6 425.2 ± 21.9 0.0933
Echocardiography parameters
 LV Dd (mm) 49.9 ± 6.3 49.5 ± 6.3 0.0803
 LV Ds (mm) 33.2 ± 8.2 32.7 ± 7.9 0.0720
 IVST (mm) 8.9 ± 1.9 8.9 ± 1.8 0.7381
 PWT (mm) 9.3 ± 6.0 9.3 ± 6.0 0.6180
 EF (%) 59.7 ± 12.3 60.0 ± 11.8 0.4006
 LV mass index (g/m2) 109.9 ± 33.5 105.1 ± 31.9 0.0270
 E-wave velocity (m/s) 68.2 ± 19.5 68.4 ± 20.0 0.7217
 A-wave velocity (m/s) 78.6 ± 21.8 80.7 ± 20.8 0.3428
 Dct (ms) 216.9 ± 58.5 223.9 ± 54.8 0.3279
 E/A ratio 0.91 ± 0.45 0.85 ± 0.31 0.2005
 e′ (cm/s) 6.08 ± 2.06 5.87 ± 1.59 0.0938
 E/e′ ratio 12.11 ± 5.20 12.34 ± 5.22 0.4858
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Prolongation of the QT interval is an important risk fac-
tor for ventricular arrhythmia and sudden death. In the 
present study, the QT interval was significantly shortened 
from baseline to 12  months (P  <  0.001), but there was 
no significant difference in the QT interval after correc-
tion for the change in HR (QTc interval) (P = 0.093). The 
basic research by Lee et al. showed that sitagliptin treat-
ment could reverse calcium regulation in cardiomyo-
cytes, which might contribute to its shortening effects 
on the QT interval in hypertensive animals [17]. In other 
research, sitagliptin was not associated with prolonga-
tion of either the QT or QTc interval at clinically relevant 
concentrations in healthy individuals [18]. Although the 
shortening of the QT interval in this study was mainly 
associated with the increased HR, the QTc interval still 
showed a trend toward shortening after sitagliptin therapy 
(P  =  0.093). Thus, it is possible that sitagliptin therapy 
might lower the risks of ventricular arrhythmias and sud-
den death due to QT interval change, but further studies 
are clearly necessary to clarify whether benefits truly exist, 
particularly in patients with diabetes and comorbid CVD.
GLP-1 receptors are located in cardiac myocytes, coro-
nary vascular endothelial cells, and smooth muscle cells; 
and, mainly in basic studies, GLP-1 has been reported to 
improve cardiac function and provide cardioprotective 
effects [9]. Nikolaidis et al. reported that GLP-1 infusion 
in patients with acute myocardial infarction improved 
LV function compared with controls receiving standard 
care [19]. However, in a randomized study of 80 diabetic 
patients with LV diastolic dysfunction, Oe et al. reported 
that sitagliptin for 6  months did not improve diastolic 
function [20]. In the present study, in which we used 
patients with similar background characteristics, there 
was no significant change in BNP levels at 12  months, 
which is a reasonably sensitive maker for the cardiac 
dysfunction and development of HF. This was the same 
for the EF and septal e′ or E/e′, which reflect diastolic 
function or end-diastolic pressure, as the diagnostic and 
therapeutic index of HF. Endothelial dysfunction may 
also result from hyperglycemia and atherosclerosis, and 
some studies have suggested that sitagliptin can improve 
endothelial dysfunction in patients with type 2 diabe-
tes and that gliptins may protect endothelial function 
through a GLP-1-dependent mechanism [21, 22]. In con-
trast, Aoyagi et al. recently reported that gliptins attenu-
ated endothelial function evaluated by flow-mediated 
vasodilatation [23]. Also, sitagliptin has been shown to 
increase adiponectin levels [24, 25], which could be asso-
ciated with the anti-atherosclerotic effects. Although the 
measurement was not performed in the present study, 
sitagliptin treatment did not reduce markers of oxida-
tive stress (urinary 8-OHdG) or inflammation (hs-CRP) 
but decreased HDL cholesterol levels. They did not affect 
endothelial function (RHI assessment) favorably. Thus, 
controversy remains around these aspects of treatment, 
and further investigation is needed.
Fig. 2 Changes in blood pressure and heart rate, and the relationship with the change in albuminuria. AU albuminuria, DBP diastolic blood pres-
sure, MAU microalbuminuria, OAU overt albuminuria, HR heart rate, M month, SBP systolic blood pressure. The values are mean ± SD or %
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Effect of sitagliptin on BP and albuminuria
We showed that sitagliptin reduced SBP and DBP inde-
pendent of ΔHbA1c and that this was associated with a 
reduction in the level of albuminuria. It might also have 
been associated with a reduction in the LV mass index. 
Relatively few studies have examined the effects of DPP-4 
inhibitors on BP in patients with diabetes [26]. Presently, 
the effects are unclear and controversial in both clinical 
and basic studies, with some investigators reporting that 
gliptins may reduce BP [27–29] and others reporting that 
these agents have no significant effects on BP [30, 31]. 
Ogawa et al. reported sitagliptin treatment affected SBP 
but not DBP in 17 patients with hypertension; however, 
in that research, the degree of decrease in HbA1c levels 
did not significantly correlate with the degree of decrease 
in SBP (r = 0.24) [28]. The results were, therefore, con-
cordant with the present result in patients with mild dia-
betes but at high CV risk.
DPP-4 inhibition with sitagliptin increases the activ-
ity of GLP-1, which has been reported to decrease uri-
nary salt uptake and increase urinary salt excretion [32]. 
In fact, 6  months of treatment with exenatide, a GLP-1 
receptor agonist, was associated with a greater reduction 
in SBP compared with placebo or insulin in pooled data 
from six trials including 2171 patients [33]. The DURA-
TION-2 study assessed the safety and efficacy of once 
weekly exenatide against maximum approved doses of 
sitagliptin, thiazolidinedione, or pioglitazone, and indi-
cated that the reduction in SBP was significantly greater 
with exenatide once weekly than with sitagliptin in all 
patients after 26 weeks of treatment [34]. The reason for 
the variation in the long-term effects of gliptins on BP 
remains unknown; however, it might be dependent on 
the patient’s physiological state because DPP-4 metabo-
lizes both prohypertensive and antihypertensive peptides 
[35]. Further clinical studies are necessary to elucidate the 
reasons for these differences. In the present study, HR sig-
nificantly increased both in ECG analysis and ambulatory 
BP measurement. It might be associated with the reactive 
activation in the sympathetic nerve system or inhibition 
of the vagal nerve system to the BP decrease as suggested 
in the treatment of GLP-1 receptor agonists [36]. How-
ever, the ΔHR was not associated with ΔSBP or ΔDBP at 
12 months in the present study, and the other mechanism 
might be suggested. The point of the long-term effects or 
CV outcomes needs to be clarified with caution [37].
The development of albuminuria is a key step in the pro-
gression of diabetic kidney disease, and worsening of albu-
minuria is a significant predictor of both progressive renal 
disease and CVD in patients with diabetes. The mecha-
nisms underlying albuminuria are complex, and improved 
insulin sensitivity, weight loss, reduced blood glucose 
levels, lower BP, and suppressed inflammation might all 
contribute to a reduction in albuminuria. Several studies 
have reported a significant correlation between improve-
ments of albuminuria and BP in patients with diabetes, 
hypertension, or nephropathy. Kawasaki et al. reported in 
a retrospective analysis that sitagliptin reduced albuminu-
ria, and that this was independently associated with reduc-
tions in BP and eGFR in 247 patients with diabetes [38]. 
In the present study, although sitagliptin did not reduce 
albuminuria overall, the reduction of BP was modestly 
associated with a decrease in albuminuria that was inde-
pendent of ΔHbA1c. Groop et al. reported that treatment 
with linagliptin for diabetic patients with renal dysfunction 
led to a significant reduction in albuminuria, independ-
ent of changes in SBP [39]. Although these findings may 
suggest direct renoprotective effects of DPP-4 inhibitors 
[40], such a blood-pressure-independent effect was not 
observed in the present study. eGFR was deteriorated dur-
ing the 12-month sitagliptin treatment, which was posi-
tively associated with ΔSBP or ΔDBP in the present study. 
Kawasaki et al. reported the similar findings and discussed 
that it might be related to the decrease in the glomeru-
lar internal pressure and be beneficial for the renal tissue 
[38]. This mechanism resembles the decrease in eGFR 
observed through the action of renin–angiotensin system 
inhibitors in decreasing glomerular internal pressure and 
albuminuria. Further evidence is needed to confirm these 
renal effects, particularly in the long-term and explore the 
underlying mechanisms in patients with diabetes [41].
Study limitations
First, this was an uncontrolled study and the effects of 
sitagliptin were only assessed by comparison of meas-
urements at three independent time points. It might be 
possible that the significant changes in several meas-
ures were affected by factors other than sitagliptin treat-
ment. However, all the patients were educated about the 
importance of diet and physical exercise, and most had 
stable medical treatment at least 1  month before the 
study inclusion. Second, the study assessments took place 
at 3 or 12 months, and may have been too short for the 
assessment of CV effects and outcomes. Therefore, the 
analysis may have been insufficient to provide conclusive 
evidence for long-term CV effects and outcomes associ-
ated with sitagliptin. Future studies must examine the BP 
lowering effects of sitagliptin and its direct influence on 
CV outcomes. Third, most of the participants had early-
stage diabetes (69.3 % had an HbA1c <7.0 %) and higher 
age (73.4  % were aged >65  years), meaning that our 
results cannot be extrapolated to all patients with diabe-
tes and high CV risk. Finally, our study design also led to 
the exclusion of some patients with severe chronic kidney 
disease or end-stage renal disease, which limits the appli-
cability of the data in these settings.
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Conclusion
We conducted a prospective, multicenter, observational 
study of 205 patients with type 2 diabetes at high risk of 
CVD who were treated with sitagliptin for 12  months. 
The efficacy of sitagliptin for glycemic control was dem-
onstrated by the higher baseline HbA1c level and the 
reduction of hs-CRP levels. Sitagliptin also showed BP 
lowering effects over the 12-month study period associ-
ated with the prevention of microalbuminuria progres-
sion. However, there were no beneficial effects on cardiac 
and endothelial function or on serum BNP, hs-TnT, and 
urinary 8-OHdG levels. We conclude that in Japanese 
patients with diabetes at high risk of CVD, sitagliptin 
had beneficial effects on BP and glycemic control over 
12 months and it might offer long-term advantages in the 
management of diabetes with comorbid CVD.
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